Active Biotech Ab

Teva Pharmaceutical Industries Limited

Acadia Pharmaceuticals Inc.

Active Biotech Ag

Karl Erik Jansson

Tomas Fristedt

Aharon Eyal

Roger Olsson

Muhammad Safadi

Daniella Licht

Ioana Lovinger

Ethan S Burstein

Anders Björk

Hans Wännman

Niklas Patrik Sköld

Henrik Von Wachenfeldt

Larisa Yudina Wahlström

Björn Gustav Borgström

Gunnar Hedlund

Anders K Bjork

Anders Bj&ouml;rk

Stig J&ouml;nsson

Magnus Gustav Wilhelm Bergner

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Compounds, salts thereof and methods for treatment of diseases

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3'-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.

Stable laquinimod preparations

A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; andat least one pharmaceutical excipient;said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

Crystalline salts of quinoline compounds and methods for preparing them

A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II)  A crystalline salt of formula (II) and a process for preparing said salt.

Compositions containing quinoline compounds

A process for the preparation of the compounds of general formula (I) wherein in a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80 and 200&#xb0; C.

Process for the manufacture of quinoline derivatives

A compound of formula (I) wherein A pharmaceutical composition comprising a compound of formula (I), a method of treating malignant tumours or diseases resulting from autoimmunity or pathologic inflammation.

Compounds

A process for the preparation of the compounds of general formula (I)wherein R is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; Ris selected from the methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, methylthio, ethylthio, n-propylthio, methylsulphinyl, ethylsulphinyl, fluoro, chloro, bromo, trifluoromethyl, and OCHF; wherein x=0-2, y=1-3 with the proviso that x+y=3; Ris hydrogen; or Rand Rtaken together are methylenedioxy; R' is selected from methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, and OCHF, wherein x=0-2, y=1-3 with the proviso that x+y=3; R&#x2033; is selected form hydrogen, fluoro and chloro, with the proviso that R&#x2033; is selected from fluoro and chloro only when R&#x2032; is selected from fluoro and chloro; by reacting a quinoline-3-carboxylic acid ester derivative of formula A with an aniline derivative of formula Bin a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80 and 200&#xb0; C.

Growing community of inventors

Dalby, Sweden

Karl Erik Jansson